Phase I Study of Tumor Specific Potentiated Vaccine Therapy Using Cyclophosphamide Combined Epitope Peptide Cocktail for Progressive/Relapsed Solid Tumors(GI/Lung/Cervical Cancer)
KOC1, TTK, CO16(URLC10), DEPDC1, MPHOSPH1 have been identified using genome-wide expression
profile analysis by the use of cDNA microarray in the previous studies. The investigators
have determined the HLA-A*2402 restricted epitope peptides respectively derived from KOC1,
TTK, CO16(URLC10), DEPDC1, and MPHOSPH1 showed strong INF-gamma production when stimulated
with the appropriate targets expressing the appropriate protein and HLA-A*2402. Furthermore,
when vaccinated these peptides, specific CTLs were determined after the vaccination.
Therefore the investigators focused on the prevention of further expansion of the solid
tumors highly expressing these 5 proteins using these 5 peptides.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
safety of the cyclophosphamide combined tumor specific epitope peptide cocktail
Kenzaburo Tani, MD,phD
Medical Institute of Bioregulation, Kyushu University
Japan: Ministry of Health, Labor and Welfare